09 February 2021
ROCHESTER, Mich., Feb. 08, 2021 -- OptimizeRx Corporation (Nasdaq: OPRX) (“OptimizeRx”), a leading provider of digital health solutions for life science companies, physicians and patients, today announced it has commenced an underwritten public offering of shares of its common stock. OptimizeRx is expected to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock being offered at the public offering price, less underwriting discounts and commissions. All of the shares will be offered by OptimizeRx.
OptimizeRx Corporation (NASDAQ: OPRX) is a pioneering digital health company that provides healthcare communications solutions for life sciences to engage in streamlined, outcomes-focused dialogue with healthcare providers and patients. Connecting more than half of healthcare providers in the US through a proprietary electronic health network, the OptimizeRx digital health and communications platform is a SaaS solution supporting treatment access and adherence by advancing affordability and transparency. The platform unlocks novel patient and provider touchpoints for life sciences along the complete longitudinal patient journey, from both ambulatory and hospital point-of-care, to retail pharmacy, through patient engagement outside the care setting.
OptimizeRx Corporation
+1 (248) 651-6568